Furthermore, in human ovarian carcinoma and cutaneous T-cell lymphoma (CTCL and Sezary syndrome), the TNFR2 antagonist reduced the ovarian carcinoma development by inducing both cancer cell death and TA-Tregs depletion [188,189] but has little inhibitory effects on blood Tregs or Tregs from healthy donors, likely due to their lower expression of TNFR2. Here, TNFRSF1B is linked to primary cutaneous T-cell non-Hodgkin lymphoma.